Material and methods We conducted a search of clinical trials of these drugs, phase III, double-blind, controlled with methotrexate or placebo, efficacy evaluated at 12 weeks or next, adults diagnosed with PP and uncontrolled disease with topical treatments and/or phototherapy. The 75% reduction in the Psoriasis Area and Severity index was used as the main variable (PASI75). An indirect comparison (IC) of cyclosporin versus fumarates and dimethylfumarate versus methotrexate was performed using the Bucher method, using the Indirect Treatment Comparisons calculator from the Canadian Agency for Health Technology Assessment. For cyclosporine with more than one published study, a previous meta-analysis was performed (Der Simonian-Laird method), using the Joaquin Primo calculator. Considering that the failure can be recovered with an effective second line, it was taken as delta value, for PASI75 the value in previous published studies of IC of biological in PP, 15%. The results were analysed graphically and the relative position of the 95% CI and the equivalence margin were observed. To establish the positioning, the ATE Guide was followed.

Results Included four clinical trials, two of ciclosporin, one of dimethylfumarate and one of fumarates. The acitretin studies were excluded because they did not meet the inclusion criteria. The difference in PASI75 expressed as RAR (IC95%) of methotrexate versus dimethylfumarate, and ciclosporin versus fumarates, was: 2.2% (-22,2;26,6) y 17 (-14,83;48,83). Applying the ATE Guide, methotrexate and dimethylfumarate can be declared ATE, being the probability of clinically relevant difference <50% (most of the 95% CI is in the equivalence range) and the failure does not involve serious/irreversible damage. Cyclosporine and fumarates could not be considered ATE (the RAR exceeded the delta with more than 50% probability so that the difference was clinically relevant).

Conclusion Dimethylfumarate and methotrexate could be considered ATE. Cyclosporin and fumarates could not be considered ATE. For a definitive statement of ATE, the criteria of safety and adequacy should be considered.

REFERENCES AND/OR ACKNOWLEDGEMENTS

No conflict of interest.

2SPD-003 MONITORING THE USE OF LINEZOLID IN A THIRD-LEVEL HOSPITAL

R Sanabrias*, C Folguera, M Calvo, B Menchén, MD García, A Repilado, A Sánchez. Hospital Universitario Puerta de Hierro, Servicio de Farmacia, Madrid, Spain

10.1136/ejhp-2019-eahpconf.43

Background The consequences of misuse of antibiotics can be very serious for patients and affect health systems and the community as a whole.

Purpose To analyse the evolution of linezolid (LNZ) consumption from 2009 to 2017 in general in the hospital and in critical care services (Anaesthesia-Resuscitation (A-R) and Intensive Care Unit (ICU)), and see if the introduction of the LNZ generic produced an increase in its use.

Material and methods Observational and retrospective study in a tertiary level hospital. The Farmatools program was used to obtain annual consumption from 2009 to 2017, both included, of the three available LNZ presentations (tablets, vials and oral suspension). The same information was obtained

from the A-R and ICU services. The defined daily doses (DDD)/100 stays for the 9 years of the study were calculated on an annual basis. The differences in the LNZ consumption of each year with respect to the previous year were analysed in a general way for the hospital and for the A-R and ICU services. The introduction of the LNZ generic in the hospital was in 2016.

Results The table shows: (A)% variation of global LNZ consumption by years; (B) DDD/100 stays for years of LNZ; and% variation of consumption in A-R (C) and ICU (D) services. It is observed that as of 2015 there was a considerable increase in the consumption of LNZ. After analysing its use in critical patients, we observed that A-R increased consumption in 2017 (14.5%). In ICU there was a very significant increase (54.35%) during the year of availability of the generic and it was maintained during 2017. The introduction of the generic and the associated price decrease could relax the monitoring of the prescription of this antibiotic.

Conclusion The increase in LNZ consumption appeared one year before the availability of the generic. In the critical units, the consumption was affected differently, increasing in A-R less and one year later than in ICU, in which it increased very significantly and coinciding with the access to the generic. The introduction of the LNZ generic contributed, along with other factors, to explaining the increase in consumption of it in our hospital.

REFERENCES AND/OR ACKNOWLEDGEMENTS

https://ejhp.bmj.com/content/24/Suppl_1/A67.1

https://ejhp.bmj.com/content/24/Suppl_1/A230.1

https://ejhp.bmj.com/content/22/Suppl_1/A93.1

No conflict of interest.

2SPD-004 DRUG CONSUMPTION DATA FOR GUIDING ANTIBIOTIC USE RATIONALISATION IN A SURGICAL DEPARTMENT

¹R Benko*, ¹G Soos, ¹M Matuz, ¹G Fungie, ²M Szabo, ¹M Csatornai, ³G Bodo, ⁴Z Peto. ¹University of Szeged, Clinical Pharmacy, Szeged, Hungary; ²University of Szeged, Surgical, Szeged, Hungary; ³University of Szeged, Central Pharmacy, Szeged, Hungary; ⁴University of Szeged, Emergency Medicine, Szeged, Hungary

10.1136/ejhp-2019-eahpconf.44

Background An antibiotic stewardship programme was set up recently in the University Hospital.

As a first step we intended to assess antibiotic use and identify problematic areas.

Purpose The aim of the present study is to map antibiotic use in a tertiary care surgical unit.

Material and methods Data was collected on systemic antibiotics delivered from the central pharmacy to the department between 2010 and 2017. Antibiotics were classified according to the Anatomical Therapeutic Chemical index. Consumption was analysed by the WHO Defined Daily Dose (DDD) method, considering the new DDDs assigned and valid from January 2019. Consumption data in DDD was standardised for 100 patient-days. Quality was assessed by the DU90 method.

Results The antibiotic use of the surgical department was more than 20,000 DDDs each year with no particular trend in use, and in different years it was responsible for 14.5% and 16.8% of total systemic antibiotic use of the university.